Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
19 déc. 2024 07h30 HE
|
Xilio Therapeutics, Inc.
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed...
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
16 déc. 2024 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 déc. 2024 16h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
07 nov. 2024 09h15 HE
|
Xilio Therapeutics, Inc.
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat,...
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
07 nov. 2024 09h05 HE
|
Xilio Therapeutics, Inc.
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the...
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
30 oct. 2024 09h01 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
04 oct. 2024 09h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 oct. 2024 16h15 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
28 août 2024 16h01 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
08 août 2024 07h30 HE
|
Xilio Therapeutics, Inc.
Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS...